Iadademstat + SBRT With Atezo in ES-SCLC

Summary

This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received platinum-based chemotherapy with or without immune checkpoint inhibitor therapy; participants who have achieved only stable disease at the completion of initial platinum-based treatment are eligible for enrollment.

Timeline

Start

2026-01-20

Primary completion

2030-01

Completion

2030-01

Drugs

Indications